Key clinical point: Immune checkpoint inhibitor therapy allows some patients with advanced RCC to safely undergo nephrectomy and metastasectomy.
Major finding: One patient attained pathologic response in the primary tumor (pT0), and three of four patients undergoing metastasectomy attained pathologic response in resected hepatic, pulmonary, or adrenal lesions (pM0); in addition, all patients had negative surgical margins.
Study details: Single-center retrospective cohort study of 10 patients with advanced RCC who underwent nephrectomy after receiving nivolumab with or without ipilimumab.
Disclosures: Dr. Singla disclosed that he had no relevant conflicts of interest. The study did not receive any specific funding.
Singla N et al. Urol Oncol. 2019 Sep 12. doi: 10.1016/j.urolonc.2019.08.012.